US FDA extends quality-by-design pilot for biologics
This article was originally published in SRA
The US Food and Drug Administration has extended the deadline for submitting requests to participate in its quality-by-design pilot programme for complex biotech products1. Companies now have an additional year – until 30 September 2010 – to send in their requests2.
You may also be interested in...
A draft EU guideline explains how disease registries can be used to supplement evidence in the pre-authorization phase and provide infrastructure for post-authorization evidence generation.
Companies are being encouraged to become “early adopters” of the EU Clinical Trials Information System when it goes live in December 2021.
Drug companies will be able to “play around” with the new EU Clinical Trials Information System in a secure testing environment before it goes live in approximately 15 months.